Sabra Health Care REIT heads into the back half of May with short sellers quietly pressing harder — and the Street, despite nudging targets higher, staying firmly on the fence.
Short interest has been building steadily for weeks. It now stands at 11.6% of the free float — up 4.3% on the week and 8.4% over the past month — making it one of the more meaningfully shorted names in the health care REIT space. The ORTEX short score has risen to 70.3, climbing almost two full points in the past week alone, and ranks in just the 2nd percentile of its universe on short score — meaning shorts are more crowded here than in nearly every comparable name. Days to cover has stretched to nearly 15, adding to the picture of a stock with real short-side conviction behind it.
The lending market, however, is far from alarmed. Availability remains comfortable relative to what is already borrowed. Borrow cost has ticked up — 0.58% now, 40% higher than a month ago — but at that absolute level it still reflects easy availability rather than any squeeze dynamic. The 52-week utilization peak was 29.1%, hit briefly in early April during the broader market dislocation; the current reading of 26.2% is well below that ceiling. Shorts can get in and out without meaningfully moving the borrow rate. The setup, then, is a stock where positioning is elevated and drifting higher, but the mechanics of the lending pool have not yet tightened into territory that would force a squeeze.
Options sentiment is modestly bullish and has turned more constructive through May. The put/call ratio dipped to 0.42 on Tuesday — below its 20-day mean of 0.43 — a mild contrast to the heavier hedging seen in late April when the ratio briefly touched 0.62. The z-score of -0.28 confirms positioning is near neutral. For a stock with 11.6% short interest, the relative absence of protective put demand is notable. Options traders are not piling in to bet alongside the shorts.
Analyst direction has been mildly positive. UBS raised its target to $22 from $21 this week while maintaining a Neutral rating — and Cantor Fitzgerald did exactly the same thing two days earlier. That makes four firms lifting targets since mid-February, across a range of ratings from Overweight to Hold. The mean target of $22.31 implies just over 6% upside from the current price of $20.97. The consensus is essentially a "wait and see": bulls point to occupancy recovery in the seniors housing portfolio and above-average RIDEA exposure as the growth engines; bears flag higher-than-peer leverage, an inflationary cost backdrop for operators, and a valuation near the top of its 10-year range. The P/E of 29.3 has expanded by about 1.2 turns over the past month, and the P/B of 1.77 has risen by 0.06, suggesting the re-rating is very gradual rather than a sudden re-price.
The institutional base is broadly supportive. BlackRock and Vanguard are the two largest holders with 15.2% and 14.0% of shares respectively, both adding modestly in their most recent filings. CenterSquare Investment Management — a REIT specialist — added 1.46 million shares in its latest report, bringing its stake to 1.5% of the company. Principal Global holds close to 10% and also added. The presence of dedicated REIT money alongside the index names provides a stable ownership floor, but none of the recent additions are large enough to shift the short-seller calculus materially.
The next catalyst on the calendar is a Q1 2026 earnings call, with results expected around July 31. Between now and then, the story for SBRA is whether the ongoing short-building — driven by concerns about operator stress and leverage — begins to attract the borrow pressure that would tighten the lending market, or whether a continued recovery in occupancy metrics gives longs a reason to push the stock closer to the $22 consensus target.
See the live data behind this article on ORTEX.
Open SBRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
